Glaukos Corp (GKOS)

$87.50 +1.34 (1.56%)
Market Cap 4.92B
Revenue (ttm) 383.48M
Net Income (ttm) -146.37M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -38.17%
Debt to Equity Ratio 0.00
Volume 794,000
Avg Vol 1,008,674
Day's Range N/A - N/A
Shares Out 57.14M
Stochastic %K 30%
Beta 0.78
Analysts Strong Sell
Price Target $122.38

Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patient...

Industry: Medical Devices
Sector: Healthcare
Phone: 949 367 9600
Fax: 949 367 9984
Address:
One Glaukos Way, Aliso Viejo, United States
d_risk
d_risk Aug. 4 at 10:58 PM
$GKOS - Glaukos Corporation Common Stock - 10Q - Updated Risk Factors GKOS risk factors in 2025 show expanded detail on sales volatility from Medicare changes, orphan drug competition, international regulatory and geopolitical risks, heightened legal and cybersecurity threats including AI, new debt-related risks, refined trade and reimbursement challenges, plus added anti-takeover and exclusive forum provisions; several outdated risks removed, but core themes remain. #MedicareChanges #Anti-TakeoverProvisions #ReimbursementChallenges #TradeChallenges #DebtRisks #AIRisks #LegalAndCybersecurityThreats #GeopoliticalRisks #InternationalRegulatoryRisks #OrphanDrugCompetition 🟢 Added 🟠 Removed https://d-risk.ai/GKOS/10-Q/2025-08-04
0 · Reply
FractionalShareWhale
FractionalShareWhale Jul. 31 at 8:50 PM
$GKOS 🔥👐🏽🔥
0 · Reply
ZacksResearch
ZacksResearch Jul. 31 at 6:33 PM
Glaukos sheds 2.2% after Q2 results — but is there a silver lining? 💡 📈 Revenue up 29.7% YoY on a reported basis, beating estimates by 8.1% 💰 Raised 2025 sales guidance; promising pipeline progress continues 📉 Headwinds persist from policy-related pressures See what makes $GKOS a potential buy 👉 https://www.zacks.com/stock/news/2644985/gkos-stock-falls-despite-q2-earnings-revenues-beat-guidance-raised?cid=sm-stocktwits-2-2644985-body-5262&ADID=SYND_STOCKTWITS_TWEET_2_2644985_BODY_5262
0 · Reply
ZacksResearch
ZacksResearch Jul. 31 at 4:56 PM
$GKOS beat Q2 earnings and raised guidance — so why is the stock dropping? Revenue surged, but the ongoing operating loss is still dragging sentiment. Full breakdown here 👉 https://www.zacks.com/stock/news/2644985/gkos-stock-falls-despite-q2-earnings-revenues-beat-guidance-raised?cid=sm-stocktwits-2-2644985-teaser-5184&ADID=SYND_STOCKTWITS_TWEET_2_2644985_TEASER_5184
0 · Reply
Kingofstocks0001
Kingofstocks0001 Jul. 30 at 1:58 PM
$GKOS about to explode
0 · Reply
Kingofstocks0001
Kingofstocks0001 Jul. 25 at 9:08 PM
$GKOS to the moon
0 · Reply
ZacksResearch
ZacksResearch Jul. 9 at 1:46 PM
Is $GKOS a hidden gem in the eye care sector? 👁️ 🚀 Q1 revenues soared 25% YoY, fueled by the iDose TR implant's strong uptake, and full-year guidance remains robust. 🌍 International interventional glaucoma sales up 15%, with promising adoption of MIGS tech as a global standard. See what makes the investment case strong for GKOS 👉 https://www.zacks.com/stock/news/2568730/glaukos-ramps-up-idose-tr-battles-legacy-and-reimbursement-risks?cid=sm-stocktwits-2-2568730-body-1036&ADID=SYND_STOCKTWITS_TWEET_2_2568730_BODY_1036
0 · Reply
ZacksResearch
ZacksResearch Jul. 9 at 11:44 AM
$GKOS crushed Q1 on iDose TR strength — but is the party already over? Record-breaking sales from iDose TR drove the quarter, but looming reimbursement issues and legacy product declines could pressure the near-term outlook. Full breakdown of the risks and momentum here 👉 https://www.zacks.com/stock/news/2568730/glaukos-ramps-up-idose-tr-battles-legacy-and-reimbursement-risks?cid=sm-stocktwits-2-2568730-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2568730_TEASER
0 · Reply
DonCorleone77
DonCorleone77 Jun. 25 at 9:38 PM
$GKOS Glaukos announces E.U. MDR certification for iStent infinite The company states: "Glaukos announced it has received European Union Medical Device Regulation certification for iStent infinite, along with several of its other leading micro-invasive glaucoma surgery technologies, including iStent inject W. Glaukos' iStent trabecular micro-bypass stenting platform primarily involves the insertion of a micro-scale surgical devices designed to reduce intraocular pressure by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma."
0 · Reply
Estimize
Estimize Jun. 19 at 12:03 PM
Wall St is expecting -0.26 EPS for $GKOS Q2 [Reporting 07/30 AMC] http://www.estimize.com/intro/gkos?chart=historical&metric_name=eps&utm_c
0 · Reply
Latest News on GKOS
Glaukos Corporation (GKOS) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 5:15 AM EDT - 4 days ago

Glaukos Corporation (GKOS) Q2 2025 Earnings Call Transcript

Glaukos Announces Second Quarter 2025 Financial Results

Jul 30, 2025, 4:05 PM EDT - 5 days ago

Glaukos Announces Second Quarter 2025 Financial Results

Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30

Jul 9, 2025, 7:00 AM EDT - 26 days ago

Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30

Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies

Jun 25, 2025, 4:05 PM EDT - 5 weeks ago

Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies

Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell

Jun 25, 2025, 7:00 AM EDT - 5 weeks ago

Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell

Glaukos Announces Participation in Upcoming Investor Conferences

May 13, 2025, 7:00 AM EDT - 2 months ago

Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 10:05 PM EDT - 3 months ago

Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript

Glaukos Announces First Quarter 2025 Financial Results

Apr 30, 2025, 4:05 PM EDT - 3 months ago

Glaukos Announces First Quarter 2025 Financial Results

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

Apr 29, 2025, 11:30 AM EDT - 3 months ago

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

ACLX BSX DHR INSM ISRG LLY RDNT

Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Apr 23, 2025, 7:00 AM EDT - 3 months ago

Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Glaukos Announces the Release of its 2024 Sustainability Report

Apr 16, 2025, 7:00 AM EDT - 3 months ago

Glaukos Announces the Release of its 2024 Sustainability Report

Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

Apr 9, 2025, 7:00 AM EDT - 4 months ago

Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

Mar 11, 2025, 7:00 AM EDT - 5 months ago

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery

Feb 24, 2025, 9:12 AM EST - 5 months ago

FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

Feb 24, 2025, 7:00 AM EST - 5 months ago

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition

Feb 21, 2025, 10:27 AM EST - 5 months ago

Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition

Glaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript

Feb 21, 2025, 4:29 AM EST - 5 months ago

Glaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

Feb 20, 2025, 4:05 PM EST - 5 months ago

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

Jan 23, 2025, 7:00 AM EST - 6 months ago

Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform

Jan 14, 2025, 4:05 PM EST - 7 months ago

Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform

Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday

Dec 31, 2024, 8:59 AM EST - 7 months ago

Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

Dec 23, 2024, 7:00 AM EST - 8 months ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

Glaukos: Still Bullish, But Embedded Expectations Are Now High

Dec 21, 2024, 7:04 AM EST - 8 months ago

Glaukos: Still Bullish, But Embedded Expectations Are Now High

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Dec 17, 2024, 7:00 AM EST - 8 months ago

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

Dec 2, 2024, 2:29 PM EST - 8 months ago

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

ISRG NVRO SYK

Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds

Nov 5, 2024, 12:21 PM EST - 9 months ago

Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds

Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 11:03 PM EST - 9 months ago

Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript

Glaukos Announces Third Quarter 2024 Financial Results

Nov 4, 2024, 4:05 PM EST - 9 months ago

Glaukos Announces Third Quarter 2024 Financial Results

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety

Oct 16, 2024, 4:05 PM EDT - 10 months ago

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting

Oct 14, 2024, 7:00 AM EDT - 10 months ago

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting

Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4

Oct 9, 2024, 7:00 AM EDT - 10 months ago

Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4

Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement

Sep 23, 2024, 1:30 AM EDT - 11 months ago

Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement

Glaukos Corporation (GKOS) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 8:57 PM EDT - 1 year ago

Glaukos Corporation (GKOS) Q2 2024 Earnings Call Transcript

Glaukos Announces Second Quarter 2024 Financial Results

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Glaukos Announces Second Quarter 2024 Financial Results

This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Jul 10, 2024, 9:05 AM EDT - 1 year ago

This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

V HELE LZ SPOT

Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31

Jul 10, 2024, 7:00 AM EDT - 1 year ago

Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31

Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock

Jun 14, 2024, 7:00 AM EDT - 1 year ago

Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock

Glaukos Corporation (GKOS) Q1 2024 Earnings Call Transcript

May 1, 2024, 8:42 PM EDT - 1 year ago

Glaukos Corporation (GKOS) Q1 2024 Earnings Call Transcript

Glaukos Announces First Quarter 2024 Financial Results

May 1, 2024, 4:05 PM EDT - 1 year ago

Glaukos Announces First Quarter 2024 Financial Results

Glaukos Announces the Release of its 2023 Sustainability Report

Apr 16, 2024, 4:05 PM EDT - 1 year ago

Glaukos Announces the Release of its 2023 Sustainability Report

Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1

Apr 10, 2024, 7:00 AM EDT - 1 year ago

Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1

Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)

Apr 3, 2024, 7:00 AM EDT - 1 year ago

Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)

Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

Glaukos Corporation (GKOS) Q4 2023 Earnings Call Transcript

Feb 21, 2024, 11:13 PM EST - 1 year ago

Glaukos Corporation (GKOS) Q4 2023 Earnings Call Transcript

Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results

Feb 21, 2024, 4:05 PM EST - 1 year ago

Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results

Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21

Jan 31, 2024, 7:00 AM EST - 1 year ago

Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance

Jan 9, 2024, 7:00 AM EST - 1 year ago

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance

Alger's Amy Zhang gives her top small-cap stock picks for 2024

Jan 5, 2024, 7:31 AM EST - 1 year ago

Alger's Amy Zhang gives her top small-cap stock picks for 2024

NTRA

Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant)

Dec 14, 2023, 7:00 AM EST - 1 year ago

Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant)

Glaukos Announces Participation in Stifel Healthcare Conference

Nov 7, 2023, 7:00 AM EST - 1 year ago

Glaukos Announces Participation in Stifel Healthcare Conference

d_risk
d_risk Aug. 4 at 10:58 PM
$GKOS - Glaukos Corporation Common Stock - 10Q - Updated Risk Factors GKOS risk factors in 2025 show expanded detail on sales volatility from Medicare changes, orphan drug competition, international regulatory and geopolitical risks, heightened legal and cybersecurity threats including AI, new debt-related risks, refined trade and reimbursement challenges, plus added anti-takeover and exclusive forum provisions; several outdated risks removed, but core themes remain. #MedicareChanges #Anti-TakeoverProvisions #ReimbursementChallenges #TradeChallenges #DebtRisks #AIRisks #LegalAndCybersecurityThreats #GeopoliticalRisks #InternationalRegulatoryRisks #OrphanDrugCompetition 🟢 Added 🟠 Removed https://d-risk.ai/GKOS/10-Q/2025-08-04
0 · Reply
FractionalShareWhale
FractionalShareWhale Jul. 31 at 8:50 PM
$GKOS 🔥👐🏽🔥
0 · Reply
ZacksResearch
ZacksResearch Jul. 31 at 6:33 PM
Glaukos sheds 2.2% after Q2 results — but is there a silver lining? 💡 📈 Revenue up 29.7% YoY on a reported basis, beating estimates by 8.1% 💰 Raised 2025 sales guidance; promising pipeline progress continues 📉 Headwinds persist from policy-related pressures See what makes $GKOS a potential buy 👉 https://www.zacks.com/stock/news/2644985/gkos-stock-falls-despite-q2-earnings-revenues-beat-guidance-raised?cid=sm-stocktwits-2-2644985-body-5262&ADID=SYND_STOCKTWITS_TWEET_2_2644985_BODY_5262
0 · Reply
ZacksResearch
ZacksResearch Jul. 31 at 4:56 PM
$GKOS beat Q2 earnings and raised guidance — so why is the stock dropping? Revenue surged, but the ongoing operating loss is still dragging sentiment. Full breakdown here 👉 https://www.zacks.com/stock/news/2644985/gkos-stock-falls-despite-q2-earnings-revenues-beat-guidance-raised?cid=sm-stocktwits-2-2644985-teaser-5184&ADID=SYND_STOCKTWITS_TWEET_2_2644985_TEASER_5184
0 · Reply
Kingofstocks0001
Kingofstocks0001 Jul. 30 at 1:58 PM
$GKOS about to explode
0 · Reply
Kingofstocks0001
Kingofstocks0001 Jul. 25 at 9:08 PM
$GKOS to the moon
0 · Reply
ZacksResearch
ZacksResearch Jul. 9 at 1:46 PM
Is $GKOS a hidden gem in the eye care sector? 👁️ 🚀 Q1 revenues soared 25% YoY, fueled by the iDose TR implant's strong uptake, and full-year guidance remains robust. 🌍 International interventional glaucoma sales up 15%, with promising adoption of MIGS tech as a global standard. See what makes the investment case strong for GKOS 👉 https://www.zacks.com/stock/news/2568730/glaukos-ramps-up-idose-tr-battles-legacy-and-reimbursement-risks?cid=sm-stocktwits-2-2568730-body-1036&ADID=SYND_STOCKTWITS_TWEET_2_2568730_BODY_1036
0 · Reply
ZacksResearch
ZacksResearch Jul. 9 at 11:44 AM
$GKOS crushed Q1 on iDose TR strength — but is the party already over? Record-breaking sales from iDose TR drove the quarter, but looming reimbursement issues and legacy product declines could pressure the near-term outlook. Full breakdown of the risks and momentum here 👉 https://www.zacks.com/stock/news/2568730/glaukos-ramps-up-idose-tr-battles-legacy-and-reimbursement-risks?cid=sm-stocktwits-2-2568730-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2568730_TEASER
0 · Reply
DonCorleone77
DonCorleone77 Jun. 25 at 9:38 PM
$GKOS Glaukos announces E.U. MDR certification for iStent infinite The company states: "Glaukos announced it has received European Union Medical Device Regulation certification for iStent infinite, along with several of its other leading micro-invasive glaucoma surgery technologies, including iStent inject W. Glaukos' iStent trabecular micro-bypass stenting platform primarily involves the insertion of a micro-scale surgical devices designed to reduce intraocular pressure by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma."
0 · Reply
Estimize
Estimize Jun. 19 at 12:03 PM
Wall St is expecting -0.26 EPS for $GKOS Q2 [Reporting 07/30 AMC] http://www.estimize.com/intro/gkos?chart=historical&metric_name=eps&utm_c
0 · Reply
JarvisFlow
JarvisFlow Jun. 18 at 10:00 AM
Mizuho updates rating for Glaukos ( $GKOS ) to Neutral, target set at 115 → 140.
0 · Reply
JarvisFlow
JarvisFlow Jun. 6 at 10:30 AM
Needham has adjusted their stance on Glaukos ( $GKOS ), setting the rating to Buy with a target price of 137 → 149.
0 · Reply
ZacksResearch
ZacksResearch May. 21 at 11:21 AM
$GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism. Discover more: https://www.zacks.com/stock/news/2475121/heres-why-you-should-retain-glaukos-stock-in-your-portfolio?cid=sm-stocktwits-2-2475121-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2475121_TEASER
0 · Reply
Kingofstocks0001
Kingofstocks0001 May. 7 at 7:45 PM
$GKOS This will double soon
1 · Reply
JarvisFlow
JarvisFlow May. 6 at 2:38 PM
Morgan Stanley updates rating for Glaukos ( $GKOS ) to Underweight, target set at 110 → 72.
1 · Reply
Kingofstocks0001
Kingofstocks0001 May. 2 at 5:37 PM
$GKOS iDose is a game changer. This stock is undervalued. Wouldn’t be surpised as it rises to $200.
0 · Reply
mikesterz7
mikesterz7 May. 2 at 1:01 AM
$GKOS Wells Fargo downgraded Glaukos to Equal Weight from Overweight with a price target of $86, down from $160. The growth runway for iDose is priced into the shares while the base business offers no upside, the firm tells investors in a research note.
0 · Reply
JarvisFlow
JarvisFlow May. 1 at 3:44 PM
Truist Securities updates rating for Glaukos ( $GKOS ) to Buy, target set at 140 → 135.
0 · Reply
JarvisFlow
JarvisFlow May. 1 at 1:00 PM
Wells Fargo updates rating for Glaukos ( $GKOS ) to Equal-Weight, target set at 160 → 86.
0 · Reply
GetVector
GetVector May. 1 at 12:55 PM
Vector Intelligence (VI) is an algorithm designed to predict potential outsized intraday moves. VI will select up to 4 stocks per day. Today's VI stocks: $CFLT, $GKOS, $TTMI.
0 · Reply
briefingcom
briefingcom May. 1 at 12:07 PM
Gapping down: $ARVN -31.3% $OGN -15.4% $CFLT -10.9% $GKOS -9.9% $AGI -9.2%
0 · Reply
anachartanalyst
anachartanalyst May. 1 at 12:01 PM
$GKOS https://anachart.com/wp-content/uploads/ana_temp/1746100905_soc-img.jpg
0 · Reply